{"id":"https://openalex.org/W2002887528","doi":"https://doi.org/10.1016/j.bmc.2010.05.057","title":"Discovery of orally available spirodiketopiperazine-based CCR5 antagonists","display_name":"Discovery of orally available spirodiketopiperazine-based CCR5 antagonists","publication_year":2010,"publication_date":"2010-05-26","ids":{"openalex":"https://openalex.org/W2002887528","doi":"https://doi.org/10.1016/j.bmc.2010.05.057","mag":"2002887528","pmid":"https://pubmed.ncbi.nlm.nih.gov/20542438","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7566811"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmc.2010.05.057","doi":"https://doi.org/10.1016/j.bmc.2010.05.057","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmc.2010.05.057","pdf_url":null,"source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7566811","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004486443","display_name":"Rena Nishizawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Rena Nishizawa","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan. r.nishizawa@ono.co.jp","Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan. r.nishizawa@ono.co.jp","institution_ids":["https://openalex.org/I4210112155"]},{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110128550","display_name":"Toshihiko Nishiyama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshihiko Nishiyama","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073476292","display_name":"Katsuya Hisaichi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Katsuya Hisaichi","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029571817","display_name":"Keisuke Hirai","orcid":"https://orcid.org/0000-0003-2665-9834","observed_orcids":["https://orcid.org/0000-0003-2665-9834"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Keisuke Hirai","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089615815","display_name":"Hiromu Habashita","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiromu Habashita","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109092983","display_name":"Yoshikazu Takaoka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshikazu Takaoka","raw_affiliation_strings":["Fukui Research Institute, Ono Pharmaceutical Co., Ltd, Technoport, Yamagishi, Mikuni, Sakai, Fukui 913-8538, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fukui Research Institute, Ono Pharmaceutical Co., Ltd, Technoport, Yamagishi, Mikuni, Sakai, Fukui 913-8538, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111913164","display_name":"Hideaki Tada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hideaki Tada","raw_affiliation_strings":["Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035586802","display_name":"Kenji Sagawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kenji Sagawa","raw_affiliation_strings":["Ono Pharmaceutical Co., Ltd, Kyutaro, Chuoh, Osaka 541-0056, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ono Pharmaceutical Co., Ltd, Kyutaro, Chuoh, Osaka 541-0056, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110700319","display_name":"Shiro Shibayama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shiro Shibayama","raw_affiliation_strings":["Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055989025","display_name":"Kenji Maeda","orcid":"https://orcid.org/0000-0002-9424-1491","observed_orcids":["https://orcid.org/0000-0002-9424-1491"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I96036126","display_name":"Kumamoto University","ror":"https://ror.org/02cgss904","country_code":"JP","type":"education","lineage":["https://openalex.org/I96036126"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Kenji Maeda","raw_affiliation_strings":["Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan","Experimental Retrovirology Section, HIV & AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, MD 20892, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan","institution_ids":["https://openalex.org/I96036126"]},{"raw_affiliation_string":"Experimental Retrovirology Section, HIV & AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034448543","display_name":"Hiroaki Mitsuya","orcid":"https://orcid.org/0000-0001-9274-3853","observed_orcids":["https://orcid.org/0000-0001-9274-3853"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I96036126","display_name":"Kumamoto University","ror":"https://ror.org/02cgss904","country_code":"JP","type":"education","lineage":["https://openalex.org/I96036126"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Hiroaki Mitsuya","raw_affiliation_strings":["Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan","Experimental Retrovirology Section, HIV & AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, MD 20892, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan","institution_ids":["https://openalex.org/I96036126"]},{"raw_affiliation_string":"Experimental Retrovirology Section, HIV & AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044537872","display_name":"Hisao Nakai","orcid":"https://orcid.org/0000-0001-9633-0255","observed_orcids":["https://orcid.org/0000-0001-9633-0255"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisao Nakai","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065716160","display_name":"Daikichi Fukushima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Daikichi Fukushima","raw_affiliation_strings":["Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tsukuba Research Institute, Ono Pharmaceutical Co., Ltd, Ibaraki 300-424, Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110809551","display_name":"Masaaki Toda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masaaki Toda","raw_affiliation_strings":["Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Minase Research Institute, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan","institution_ids":["https://openalex.org/I4210112155"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5004486443"],"corresponding_institution_ids":["https://openalex.org/I4210112155"],"apc_list":{"value":3960,"currency":"USD","value_usd":3960},"apc_paid":null,"fwci":1.8593,"has_fulltext":false,"cited_by_count":18,"citation_normalized_percentile":{"value":0.84094115,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"18","issue":"14","first_page":"5208","last_page":"5223"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9110999703407288,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9110999703407288,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11532","display_name":"Chemokine receptors and signaling","score":0.022700000554323196,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.011800000444054604,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ccr5-antagonist","display_name":"CCR5 antagonist","score":0.9390000104904175},{"id":"https://openalex.org/keywords/anti-hiv-activity","display_name":"anti-HIV activity","score":0.8640000224113464},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.9490000009536743},{"id":"https://openalex.org/keywords/carboxylic-acids","display_name":"carboxylic acids","score":0.7609999775886536},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7289999723434448},{"id":"https://openalex.org/keywords/hiv-entry-inhibitors","display_name":"HIV entry inhibitors","score":0.4480000138282776},{"id":"https://openalex.org/keywords/drug-design-and-synthesis","display_name":"drug design and synthesis","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.913388192653656},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.729832649230957},{"id":"https://openalex.org/C37044404","wikidata":"https://www.wikidata.org/wiki/Q5009692","display_name":"CCR5 receptor antagonist","level":5,"score":0.7189687490463257},{"id":"https://openalex.org/C114373084","wikidata":"https://www.wikidata.org/wiki/Q273499","display_name":"Chemical synthesis","level":3,"score":0.6082084774971008},{"id":"https://openalex.org/C2779074116","wikidata":"https://www.wikidata.org/wiki/Q134856","display_name":"Carboxylic acid","level":2,"score":0.5783942341804504},{"id":"https://openalex.org/C3017990168","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Orally active","level":3,"score":0.5679190754890442},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.5412144660949707},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.5261325836181641},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.5045820474624634},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.49791932106018066},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.39967456459999084},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.29477453231811523},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.185735821723938},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17326214909553528},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.0},{"id":"https://openalex.org/C12823836","wikidata":"https://www.wikidata.org/wiki/Q24720618","display_name":"Chemokine receptor","level":4,"score":0.0},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018938","descriptor_name":"Caco-2 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D019713","descriptor_name":"Receptors, CCR5","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065100","descriptor_name":"CCR5 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.bmc.2010.05.057","doi":"https://doi.org/10.1016/j.bmc.2010.05.057","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmc.2010.05.057","pdf_url":null,"source":{"id":"https://openalex.org/S10422866","display_name":"Bioorganic & Medicinal Chemistry","issn_l":"0968-0896","issn":["0968-0896","1464-3391"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:20542438","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20542438","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7566811","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7566811","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Bioorg Med Chem","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:7566811","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7566811","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Bioorg Med Chem","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7561829693","display_name":"Study of Structures of CCR5 and Its Interactions with CCR5 Inhibitors","funder_award_id":"Z01BC011109","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W82820957","https://openalex.org/W1602000691","https://openalex.org/W1975988456","https://openalex.org/W1981440980","https://openalex.org/W1981644527","https://openalex.org/W1996183144","https://openalex.org/W2005228785","https://openalex.org/W2020170393","https://openalex.org/W2033102125","https://openalex.org/W2038196400","https://openalex.org/W2049872439","https://openalex.org/W2056257176","https://openalex.org/W2064397003","https://openalex.org/W2089138872","https://openalex.org/W2117819606","https://openalex.org/W2147169218","https://openalex.org/W2161911309"],"related_works":["https://openalex.org/W2020170393","https://openalex.org/W2094876127","https://openalex.org/W2110294577","https://openalex.org/W2049872439","https://openalex.org/W2911672402","https://openalex.org/W1986434893","https://openalex.org/W2056257176","https://openalex.org/W1990515631","https://openalex.org/W2104491973","https://openalex.org/W2911328831"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}